Allogenetics develops novel gene therapies to improve organ transplantation.
The lead programme ALG-115 is applied once, ex vivo, to the donor organ and is designed to reduce the organ’s immunogenicity through a targeted reduction of MHC class I and MHC class II expression. The aim is to reduce rejection and the need for long-term immunosuppression, thereby achieving a lasting improvement in transplant outcomes.
The initial focus is on lung transplantation.
Visit website (opens in a new window)